Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Genie29jon Dec 04, 2020 9:29am
109 Views
Post# 32035916

RE:RE:RE:RE:Algorithmic Trading

RE:RE:RE:RE:Algorithmic Trading

To me that is real information. When I think back to YOFOTO, it was significantly delayed, but we had no idea... 

this time, the redlining of the agreement is going quicker than expected, which to me means they will get $$ sooner than expected, which will help expedite the device. For me, Sometimes it's not just about the  black & white headlines, but in this case you need to read in between the lines. 


similarly someone tweeted to them 3 days ago, 
"When do you expect to update the community on an updated forecasted timeline for the device? With this new funding, can we expect a market ready launch / CE Mark approval of the device in 1H, 2021? #weareready #inittowinit"

RepliCel liked this tweet. No comment, just liked it. I look at that as a positive outcome 

<< Previous
Bullboard Posts
Next >>